PharmaCyte Biotech (NASDAQ:PMCB) Releases Quarterly Earnings Results

PharmaCyte Biotech (NASDAQ:PMCB) released its quarterly earnings results on Monday. The company reported $0.14 earnings per share for the quarter, reports.

PharmaCyte Biotech Stock Performance

PharmaCyte Biotech stock opened at $1.93 on Thursday. The firm has a market capitalization of $16.31 million, a price-to-earnings ratio of -1.61 and a beta of -0.22. PharmaCyte Biotech has a fifty-two week low of $1.39 and a fifty-two week high of $2.60. The stock’s fifty day moving average is $1.84 and its two-hundred day moving average is $2.04.

Institutional Investors Weigh In On PharmaCyte Biotech

A hedge fund recently raised its stake in PharmaCyte Biotech stock. K2 Principal Fund L.P. boosted its holdings in shares of PharmaCyte Biotech, Inc. (NASDAQ:PMCB) by 17.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 304,613 shares of the company’s stock after acquiring an additional 46,132 shares during the period. K2 Principal Fund L.P. owned about 3.53% of PharmaCyte Biotech worth $655,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 34.24% of the company’s stock.

PharmaCyte Biotech Company Profile

PharmaCyte Biotech, Inc, a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes.